secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001193125-23-044236
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics appoints three new directors, separates Chairman and CEO roles after activist agreement
--------------------------------------------------------------------------------

- Appointed Craig Collard, Adam Morgan (Velan), and Kevin Kotler to Board; Board expands to eight directors.
- Directors Stephen Davis and Kimberly Manhard resigned; seven of eight directors now independent.
- Company to separate Chairman and CEO roles after 2023 Annual Meeting.
- Cooperation agreement with Rubric Capital and Velan Capital includes standstill, voting commitments, and board composition terms.
- New directors will stand for election at 2023 Annual Meeting; Board committees assigned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312523044236/0001193125-23-044236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312523044236/d457589d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-044236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer